A Study of CI-1012 in HIV-Infected Patients
NCT00002196
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
HIV Infections
Interventions
DRUG:
CI-1012
Sponsor
Parke-Davis